Press & Media

Denka Signs Distribution Agreements with PlexBio for the IntelliPlex™ Instrument System and Reagents

2018.8.8


PlexBio Co., Ltd, an emerging multi-national diagnostic company, has signed the Distribution Agreement with Denka Co., Ltd. for its IntelliPlex™ 1000 πCode Processor and PlexBio™ 100 Fluorescent Analyzer for use in the Japanese life science research market. ...more

TFDA Licenses for IntelliPlex™ KRAS and KRAS+

2018.8.6


Taipei, Taiwan – August 6, 2018 - PlexBio Co., Ltd, an emerging multi-national diagnostic company, has passed GMP inspection and received export licenses from the Taiwan FDA for its CE Marked IntelliPlex™ KRAS and IntelliPlex™ KRAS Mutation Plus Kits. ...more

University "G. D'Annunzio" of Chieti Presents Data on PlexBio Technology at MDX Conference

2018.5.24


PlexBio is pleased to recognize that Dr. Nicla Borrelli from the University "G. D'Annunzio", Chieti, Italy, will be presenting at 6th International Molecular Diagnostics Europe conference at Lisbon Portugal, from May 22-24, 2018 on results from studies using PlexBio’s IntelliPlex™ multiplexing technology. ...more

Euroclone Signs Distribution Agreements with PlexBio for the IntelliPlex™ Instrument System and Reagents

2018.5.8


PlexBio Co., Ltd, an emerging multi-national diagnostic company, has signed an agreement with Euroclone S.p.A. of Milan to be the exclusive distributor its IntelliPlex™ 1000 πCode Processor and PlexBio™ 100 Fluorescent Analyzer for use in the Italian life science research market. ...more

PlexBio Presents Multiplex Mutation Analysis for Cancer Management by πCode Technology at Molecular Med Tri-Con 2018

2018.2.14


San Francisco, CA (February 14, 2018) – PlexBio Co., Ltd. presented scientific data on the development and use of a series of novel multiplex assays on the company’s IntelliplexTM instrument system at this week’s 25th Molecular Med Tri-Conference in San Francisco, CA. ...more

< 1 | 2 | 3 | >